# Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes

Study · id `cardio:ct-nct05054842` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05054842](<https://clinicaltrials.gov/study/NCT05054842>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05054842

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 174 participants.

## Technical summary

Registry record NCT05054842. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-06 (actual); primary completion 2023-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 174 participants (enrolled count; ClinicalTrials.gov record NCT05054842, source copy `cardio:ctgov-nct05054842-2023-07-10`, retrieved 2026-10-26)
- Started: 2021-12-06 (actual) (ClinicalTrials.gov record NCT05054842, source copy `cardio:ctgov-nct05054842-2023-07-10`, retrieved 2026-10-26)
- Primary completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05054842, source copy `cardio:ctgov-nct05054842-2023-07-10`, retrieved 2026-10-26)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05054842, source copy `cardio:ctgov-nct05054842-2023-07-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05054842, source copy `cardio:ctgov-nct05054842-2023-07-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05054842-2023-07-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Retagliptin phosphate tablets、metformin sustained-release tablets
- Intervention (Drug): Retagliptin phosphate placebo tablets、metformin sustained-release tablets
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: d50f23a9d8d943b158da0b6007da37803fb89c33455c2d82ab3cff1c124bb315
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
